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The pseudokinase TRIB1 controls cell function in a range of contexts, by regulating MAP
kinase activation and mediating protein degradation via the COP1 ubiquitin ligase. TRIB1
regulates polarization of macrophages and dysregulated Trib1 expression in murine
models has been shown to alter atherosclerosis burden and adipose homeostasis.
Recently, TRIB1 has also been implicated in the pathogenesis of prostate cancer,
where it is often overexpressed, even in the absence of genetic amplification. Well
described TRIB1 effectors include MAP kinases and C/EBP transcription factors, both
in immune cells and in carcinogenesis. However, the mechanisms that regulate TRIB1
itself remain elusive. Here, we show that the long and conserved 3’untranslated region
(3’UTR) of TRIB1 is targeted by miRNAs in macrophage and prostate cancer models. By
using a systematic in silico analysis, we identified multiple “high confidence” miRNAs
potentially binding to the 3’UTR of TRIB1 and report that miR-101-3p and miR-132-3p are
direct regulators of TRIB1 expression and function. Binding of miR-101-3p and miR-132-
3p to the 3’UTR of TRIB1 mRNA leads to an increased transcription and secretion of
interleukin-8. Our data demonstrate that modulation of TRIB1 by miRNAs alters the
inflammatory profile of both human macrophages and prostate cancer cells.
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INTRODUCTION
Tribbles-1 (TRIB1) is an evolutionary conserved pseudokinase
that in mammals controls a wide range of interacting signaling
pathways, such as mitogen activated protein kinases and the PI3-
kinase pathway. Its expression is detectable in most tissues; it is
highest in the bone marrow and in the thyroid gland (The
Human Protein Atlas, https://www.proteinatlas.org).
Structurally, the TRIB1 protein contains an N-terminal PEST
region, a pseudokinase domain and a C-terminal COP1-binding
region. By lacking a functional adenosine 5’-triphosphate (ATP)
binding site, TRIB1 is a catalytically inactive enzyme (1).
However, through the pseudokinase domain, TRIB1 acts as
adapter or scaffold facilitating assembly with other proteins (2–
4). TRIB1 is an established oncogene in acute myeloid leukemia
(5, 6) and has been shown to play a pivotal role in the
differentiation of anti-inflammatory M2-macrophages in the
pathogenesis of early atherosclerosis and during adipose tissue
inflammation (7–9). Additionally, TRIB1 has been reported to be
overexpressed in prostate cancer, where it controls the
expression of endoplasmic reticulum chaperone proteins and
induces M2-macrophage differentiation (10, 11). At the
transcript level, TRIB1 is highly unstable, reported to have an
mRNA half-life shorter than 1 hour (12). TRIB1 expression is
also highly variable among different cell types and tissues,
suggesting it might be subject to cell type-dependent post-
transcriptional regulation (13, 14). In fact, the 2kb long,
3’untraslated region (3’UTR) of TRIB1 mRNA represents more
than 50% of the entire sequence and is highly conserved among
different animal species. Recently, Soubeyrand and colleagues
showed that blocking transcription through actinomycin-D
dramatically reduced TRIB1 mRNA levels in HeLa cells and
Aortic Smooth Muscle cells (15), while overexpression of the
3’UTR was shown to raise levels of the endogenous mRNA in
HeLa cells (2). A major gene regulatory mechanism described in
eukaryotes is mediated by microRNAs (miRNAs) by the process
of RNA interference (RNAi). miRNAs are small non-coding
RNAs that commonly bind to the 3’UTR of the target gene, and,
via association with effector proteins, form the RNA-induced
silencing complex (RISC) that ultimately leads to RNA
degradation and inhibition of protein translation (16).
In the present work, we systematically analyzed the post-
transcriptional regulation of TRIB1 by miRNAs, with focus on
macrophages and prostate cancer models. We show that the
3’UTR of TRIB1 significantly reduces expression of a luciferase
reporter when transiently transfected into HEK293 cells, it is
enriched in miRNA-binding sites and is a direct target of
multiple miRNAs. A significant number of miRNAs predicted
to regulate TRIB1, are also silenced and/or downregulated in
prostate cancer, and therefore may contribute to the elevated
expression of this pseudokinase in this cancer. By directly
targeting TRIB1, miR-101-3p and miR-132-3p control the
inflammatory profile of human primary macrophages and
prostate cancer cells, as exemplified by enhancing the




To isolate primary human blood monocytes, up to 80 ml of
venous blood was taken from healthy donors. The study was
approved by the University of Sheffield Ethics Committee
(Reference Numbers: 031330, SMBRER310) in accordance with
the Declaration of Helsinki and written informed consent was
obtained from all volunteers.
Animal Experiments
Mice were handled in accordance with UK legislation (1986)
Animals (Scientific Procedures) Act. Mouse experiments were
approved by the University of Sheffield Project Review
Committee and carried out under a UK Home Office Project
License (70/7992). Myeloid specific Trib1 conditional knockout
(KO) mice were generated by crossing Trib1 fl/fl mice that
contain flanking loxP sites around the second exon of Trib1
and crossing them with Lyz2Cre recombinase transgenic mice
(www.jax.org/strain/004781). The resulting mice; Trib1 fl/fl x
Lyz2Cre (Trib1mKO) have all but the first 120 amino acids of
TRIB1 excised. Myeloid specific Trib1 over-expressor transgenic
mice were generated by crossing Rosa26.Trib1mice with Lyz2Cre
recombinase transgenic mice as described above. The resulting
mice; Rosa26.Trib1 x Lyz2Cre (Trib1mTg) over-express Trib1
transgene by ~2.5 fold as previously described by Johnston et al.
(9). Wild- type litter mates (Trib1mWT) were used as controls. All
mice used were congenic on a C57BL/6J background and were
housed in a controlled environment with a 12-h light/dark cycle,
at 22°C in Optimice individually ventilated cages (Animal Care
Systems) and given free access to a standard chow diet (#2918;
Harlan Teklad) and water. Mice were sacrificed humanely by
cervical dislocation at 12–13 weeks of age.
Isolation of Human Monocyte-Derived
Macrophages (MDMs)
Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll–Paque Plus (GE Healthcare) density centrifugation and
CD14+ monocytes were selected by positive magnetic separation
using CD14 microbeads (Miltenyi Biotec). Monocytes were then
cultured in complete media for seven days: RPMI-1640 (Gibco),
10% (v/v) low-endotoxin heat-inactivated FBS (PanBiotech), 1%
(v/v) L-glutamine (Gibco) and 1% (v/v) penicillin/streptomycin
(Gibco). Recombinant human (rh) M-CSF (100 ng/ml,
Peprotech/Immunotools) was added to the media to allow the
differentiation of monocytes into macrophages (MDMs). After 7
days of differentiation, MDMs were polarized into pro- (M1) and
anti-(M2a) inflammatory macrophages for 24 h, using 20 ng/ml
IFN-g (Human, Peprotech) and 100 ng/ml E. col i
lipopolysaccharide (Serotype R515 TLR grade TM, Enzo Life
Sciences) and 20 ng/ml IL–4 (Human, Peprotech), respectively.
Established Cell Lines
HEK293T cells were obtained from ATCC® (UK) and grown in
Dulbecco ’s modified Eagle ’s medium (DMEM, Gibco)
supplemented with 10% (v/v) low-endotoxin heat-inactivated
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FBS (PanBiotech) and 1% (v/v) penicillin/streptomycin (Gibco).
Immortalized bone marrow-derived macrophages (iBMDMs)
were kindly provided by D. Brough (University of Manchester)
and generated as described by Hornung et al. (17), were grown in
DMEM further supplemented with 1% (v/v) sodium pyruvate
(Gibco) and 1% (v/v) sodium bicarbonate (Gibco). HEK293T
cells and iBMDMs were grown in T75 flasks passaged every 2–3
days in a 1:10 ratio, using trypsin/EDTA (Lonza) and cell
scrapers (Biofil), respectively. Prostate cell lines used were PC3
and LNCAP as cancer cells and PWR1E and RWPE1 as normal
prostatic epithelial cell controls. PC3 were grown in complete
DMEM (Gibco) and LNCAP in RPMI-1640 plus 10% (v/v) low-
endotoxin heat-inactivated FBS (PanBiotech), 1% (v/v)
penicillin/streptomycin (Gibco) and 1% (v/v) L-glutamine
(Lonza). PWR1E and RWPE1 were cultured in Keratinocyte
Serum Free Media (K-SFM, Gibco) supplied with 1% (v/v)
penicillin/streptomycin, 0.05 mg/ml bovine pituitary extract
(BPE) and 5 ng/ml human recombinant epidermal growth
factor (EGF), both provided with the K-SFM kit.
miRNA-Target Prediction Analysis
miRNA-target prediction analysis was carried out using seven
different algorithms (miRanda 2010 (18), TargetScan v.7.2 (19),
miRDB v.6 (20), StarBase 2019-2020 (21), miRwalk v.2 (22),
Tarbase v.8 (23), and microT-CDS v.5 (24). All tools were used
online, except miRanda which was downloaded and used locally
as independent software, employing the default parameters.
miRbase v.22 (25, 26) was used to download the list of “high-
confidence” miRNAs, based on deep sequencing data. The total
number of miRNAs predicted to target the 3’UTR of TRIB1 by
each tool were imported in mySQL Database (pgAdmin v.4) and
filtered using structural queries (for example “intersect” function
to intersect tables and find “common” elements). We then
selected only miRNAs predicted by at least 3 different tools. To
identify miRNAs dysregulated in prostate cancer, we used the
microRNA Cancer Association Database miRCancer, which is
based on published literature [http://mircancer.ecu.edu/ (27)].
Transient Transfection
Small RNA-based transfection was carried out using Viromer Green
for primary cells and Viromer Blue for established cell lines
(Lipocalyx), while DNA-based transfection was performed using
Lipofectamine 3000 (Invitrogen). Simultaneous transfection of RNA
and DNA was achieved using Dharmafect DUO (Horizon
Discovery). TRIB1 siRNA, miRNA mimics, inhibitors, and
negative controls were purchased from Horizon Discovery
(sequences are listed in Supplementary Table 1); miR-101/TRIB1
Target site blocker (TSB) and negative control were obtained from
Qiagen. TSB are antisense oligonucleotides designed to bind to a
specific region of a miRNA-target gene, thus masking it from the
miRNA. However, the TSB does not lead to the activation of the
RISC complex; it only prevents the endogenous miRNA from




target-site-blockers/#productdetails). Each transfection experiment
was performed independently. Transfection time and RNA/DNA
concentrations are specified in each figure legend.
Immunofluorescence Staining
To assess Kupffer cell phenotype, FFPE liver tissue from mixed
gender mice was stained with F4/80 and phenotypic markers
YM1 (M2/alternatively activated) and IRF5 (M1/classically
activated). Adipose tissue macrophages were stained with F4/
80 and YM1 only. Sections were de-waxed, rehydrated and
endogenous peroxidases were blocked by incubation in 3% (v/
v) hydrogen peroxidase for 10 min at room temperature followed
by enzyme induced (trypsin) antigen retrieval (A. Menarini
Diagnostics, UK) and permeabilized with 0.1% (v/v) Triton X-
100 for 15 min. Tissues were incubated with rat anti-F4/80 and
then with a secondary biotinylated rabbit anti-rat followed by
Streptavidin-PE. Sections were then re-blocked in 5% (v/v)
donkey serum and incubated with either mouse anti-mouse
IRF5 or rabbit anti-mouse YM1 followed by either incubation
with donkey anti-mouse or donkey anti-rabbit NL493. Details of
antibodies, dilutions and incubation time can be found in
Supplementary Table 2. Tissues were then mounted with
ProLong® Gold antifade mountant with DAPI (Molecular
Probes). Fluorescent images were captured using an inverted
wide-field fluorescence microscope (Leica AF6000) and analyzed
by Image J64 (v1.51). Only cells that were F4/80+ were included
in the analysis to ensure macrophage specificity. Relative IRF5
and YM1 staining is normalized to levels of F4/80+ cells and are
representative of at least three fields of view. Specificity of
immunofluorescence staining was ascertained by using isotype
controls as exemplified in Supplementary Figure 1.
Real-Time Quantitative PCR
Total RNA isolation was performed by using the miRNeasy Mini
Kit (Qiagen) according to manufacturer instructions. The kit
enables the purification of total RNA, including small RNAs and
is based on silica-spin columns for optimal RNA binding. RNA
concentration and purity were assessed by NanoDrop™
Spectrophotometer (260/280 ratio = 1.8/2.0; 260/230 ratio =
1.8/2.0). cDNA was synthesized using iScript cDNA Synthesis
Kit (Biorad) for mRNA and miRCURY LNA RT Kit for
microRNAs (Qiagen) following manufacturer instructions.
Real-time quantitative PCR (RT-qPCR) was performed using
SYBR Green master mix (Primer Design) for the mRNA analysis;
the miRCURY LNA miRNA PCR Assay kit (Qiagen) was used
for microRNAs amplification. Primers were designed and
checked for specificity using BLAST Primer Design Tool
(https://www.ncbi.nlm.nih.gov/tools/primer-blast) and
purchased from Sigma-Aldrich; microRNA-specific primer mix
were obtained from Qiagen. Results were analyzed upon a
CFX384 C1000 Touch Thermal Cycler (Biorad), using the 2
(-Delta Ct) analysis method. Each biological sample analyzed
represents the average value of 3 technical replicates. Primer
sequences are listed in Supplementary Table 3.
Western Blotting
Proteins were extracted from cell culture plates by homogenizing
in RIPA buffer (Sigma-Aldrich), containing protease inhibitors
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(Sigma-Aldrich). The lysates were centrifuged at 4°C for 20 min
at 14,000 g and the liquid upper phase was collected. Five or ten
(depending on the specific experiment) micrograms of total
protein lysate were then loaded onto a 4% to 12% NuPAGE
Bis-Tris Gel (Invitrogen) and transferred onto Immobilon PVDF
Membrane (Merck). Primary and secondary antibodies used are
listed in Supplementary Table 2.
Enzyme-Linked Immunosorbent Assay
(ELISA)
IL-8 ELISA was carried out using DuoSet ELISA kit (R&D)
following manufacturer’s instructions. The samples were
supernatants collected after transient transfection of
human MDMs.
Molecular Cloning and Site-Directed
Mutagenesis
Molecular cloning was carried out to generate reporter and
expression plasmids by using pENTR/D-TOPO Cloning Kit
(Invitrogen). High-efficiency transformation of bacteria was
performed using 5-alpha competent E. coli (New England’s
Labs). Multiple nucleotides deletions were generated through a
site-directed mutagenesis kit according to manufacturer
instructions (Agilent). Mutagenic primer sequences are
specified in Supplementary Table 4.
Dual Luciferase Reporter Assay
HEK293 cells were transfected with a mixture of plasmids,
encoding 1) for firefly luciferase, under the control of
Thymidine Kinase minimal promoter and 2) firefly luciferase
under the control of EF1 promoter ± the TRIB1 3’UTR. Twenty-
four hours post-transfection, media was removed and cells were
washed with PBS 1X twice and then lysed using 35 ml of 1X
Passive Lysis Buffer (Promega); 5 ml of lysate was transferred
onto a Nunc 384-well polystyrene white microplate. The
substrates of Firefly luciferase (LAR II, Promega) and Renilla
luciferase (Stop & Glo, Promega) were sequentially added to the
cell lysates (1:1 ratio). From the same sample, luminescence was
measured first at 560 nm for firefly luciferase and at 480 nm for
Renilla luciferase using a microplate reader (Thermo Fisher
Scientific). Each condition was plated in triplicate. All the
readings were first normalized to the readings generated by
non-transfected cells to subtract the luminescence background
and then Renilla/Firefly ratio was calculated.
Cholesterol Efflux Assay
Cholesterol efflux assay was performed on MDMs transfected
with miR-101-3p mimic and inhibitor, 24 h post-transfection.
Cells were treated with 2.5 uM of TopFluor Cholesterol (23-
(dipyrrometheneboron difluoride)-24-norcholesterol (Avanti
Polar Lipids) for 24 h in RPMI 0.2% BSA fatty-acid free
(Sigma-Aldrich). Media was changed to only RPMI 0.2% BSA
fatty-acid free for 18 h (equilibration step). After that, 50 µg/ml
of High-Density Lipoprotein (HDL) (Biorad) was added as
cholesterol acceptor for 4 h. The media (supernatant) was
collected and cells were lysed using a solution of 1% Cholic
Acid in 100% Ethanol (Sigma-Aldrich). Both cell lysates and
supernatants were then added to a Nunc 96-well plate (black) in
triplicates and fluorescence was read using a microplate reader
(Thermo Fisher Scientific) (excitation 490 nm, emission 520
nm). Data were analyzed as described by Low et al. (28).
Statistical Analysis
All experiments were performed at least three times. Graphs and
statistical analysis were generated in GraphPad Prism 8.00
(GraphPad). Statistical methods are specified in each figure
legend. P‐values <0.05 were considered to be statistically
significant. Where appropriate, post-hoc power calculations
have confirmed the likely lack of type II error. Group sizes are
described in figure legends and, in line with conventions, for
primary cells, each N represents an independent, healthy donor.
RESULTS
Manipulation of TRIB1 Expression Alters
Liver and Adipose Tissue Macrophage
Phenotype In Vivo and Inflammatory
Markers in Monocyte-Derived
Macrophages In Vitro
We first determined the effect of myeloid-specific Trib1
overexpression and KO on tissue-resident macrophage numbers
and phenotype, employing wild-type (WT) and myeloid-specific
Trib1 knock-out and Trib1 transgenic (Tg) mice. The generation
and characterization of these strains has been reported previously
(9). First, we wanted to ascertain the consequences of altered
myeloid Trib1 levels in metabolic tissues as this gene has been
identified as a risk locus for hyperlipidaemia in a number of
GWAS analyses (29–31) but its molecular mechanism impacting
on lipid homeostasis is still incompletely understood. Dual
immunofluorescence staining of Kupffer cells (liver resident
macrophages) (Figures 1A, B) and adipose-tissue macrophages
(ATMs) (Supplementary Figure 2), revealed that while altered
Trib1 expression has no effect on the number of F4/80 positive
macrophages in these tissues (Figure 1C and Supplementary
Figure 2B), it significantly altered their phenotype (Figures 1D, E
and Supplementary Figure 2C). Specifically, Kupffer cells from
Trib1mKO mice showed a significantly elevated expression of the
pro-inflammatory transcription factor IRF-5 (n = 3), compared to
Trib1mWT (p = 0.02), while macrophages from Trib1mTgmice were
characterized by a ~50% reduction of IRF-5 positive macrophages,
compared to Trib1mWT (p = 0.04) (Figure 1D). Trib1mKO also
exhibited a reduced expression of the anti-inflammatory marker
YM-1 (~40% decrease on average), but this was not statistically
significant (p = 0.3). Conversely, macrophages from Trib1mTg
showed a ~75% increase in the expression of YM-1, compared
to Trib1mWT (p = 0.007) (Figure 1E). Similarly, ATM from
Trib1mKO mice exhibited a ~50% reduction of YM-1 expression,
compared to Trib1mWT (p = 0.01). However, Trib1mTg only had a
modest, non-significant effect (~16% increase) on YM-1
expression in ATM (p = 0.4) (Supplementary Figure 2C),
suggesting that Trib1-dependent changes in macrophage
Niespolo et al. miRNAs Control TRIB1 Expression




FIGURE 1 | Genetic manipulation of myeloid Trib1 alters Kupffer cells phenotype in vivo. (A, B) Representative images of IRF5 and YM1 immunostaining of liver
tissue sections from Trib1mWT, Trib1mKO and Trib1mTg mice. Scale: 100 µm. Enlarged image of marked area is also shown. (C) Quantification of F4/80 positive cells
relative to DAPI in liver tissue sections from Trib1mWT, Trib1mKO, and Trib1mTg mice (n = 3–9, ordinary one-way ANOVA with Sidak’s post-test, no statistical
significance p > 0.05). (D) Quantification of IRF5 positive cells relative to F4/80 in liver tissue sections from Trib1mWT, Trib1mKO, and Trib1mTg mice (n = 3–11, ordinary
one-way ANOVA with Sidak’s post-test, **p < 0.01, *p < 0.05). (E) Quantification of YM1 positive cells relative to F4/80 in liver tissue sections from Trib1mWT,
Trib1mKO and Trib1mTg mice (n = 8–12, ordinary one-way ANOVA with Sidak’s post-test, **p < 0.01, no statistical significance p > 0.05). Data are presented as
mean ± SEM. Each data point (n) represents an individual mouse. At least three independent fields of view were examined per mouse. Samples were obtained and
analyzed from three independent breeding cohorts, in total, each including WT littermate controls.
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phenotypes may be modulated by the local tissue environment.
Next, we evaluated the impact of TRIB1 overexpression on the
phenotype of human macrophages, employing transient
transfection of monocyte-derived macrophages (MDMs) with a
plasmid construct to overexpress the human TRIB1 protein. In
response to TRIB1 overexpression (shown in Supplementary
Figure 2). We observed a significant increase in the mRNA
levels of MSR1 (p < 0.05) and CD163 (p < 0.05), genes
associated with alternatively activated macrophages (Figures 2A,
B). Similarly, we observed an increase in IL-4, on average, but the
change was not statistically significant (p = 0.09) (Figure 2C).
Reduced levels of the pro-inflammatory cytokines IL-6 and IL-8
were also observed (Figures 2D, E). In addition, we measured the
levels of IL-8 protein secreted in the media by MDMs and found
that there was a significant reduction in IL-8 production by TRIB1
overexpressing cells, compared to the control (Figure 2E). These
data are consistent with previous reports (8, 32), indicating that
myeloid TRIB1 expression regulates the polarization of
macrophages, favoring an anti-inflammatory, alternatively
activated macrophage phenotype both in vivo as shown in
Trib1-deficient mice (8) and in in vitro, as demonstrated in




As TRIB1 mRNA has been reported to be highly unstable (12),
we investigated its post-transcriptional regulation by miRNAs.
The mRNA of TRIB1 encodes for a long and conserved 3’UTR
region, representing more than half of the entire sequence (Figure
3A). Additionally, the 3’UTR sequence is well conserved




FIGURE 2 | Genetic manipulation of TRIB1 alters macrophage phenotype in vitro. Relative mRNA expression of (A) MSR1, (B) CD163, (C) IL-4, (D) IL-6, and (E) IL-8
normalized to the housekeeping GAPDH and F: IL-8 (pg/ml) ELISA measured in MDMs transiently transfected with a TRIB1 overexpression plasmid and a control
plasmid. Data are presented as mean ± SEM (scatter dot plot) (n = 4–7 biological replicates, paired t-test, *p < 0.05, no statistical significance p > 0.05). Transfection
was carried out for 24 h, employing 2 µg of plasmid per well (6 well plate format). Each biological replicate represents the average of 3 technical replicates. ELISA was
performed on supernatants collected 24 h post-transfection. RT-qPCR data were analyzed using the 2(−Dct) method.
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As the majority of miRNAs have functional target sites in this
region, we evaluated the impact of the 3’UTR of TRIB1 on
mRNA stability using a luciferase reporter assay. Cloned
downstream of the renilla luciferase gene, the 3’UTR of TRIB1
led to a robust and significant decrease (> 40%) of the luciferase
activity, compared to the control lacking the UTR (p < 0.0001)
(Figure 3D), suggesting that this region contributes to the post-
transcriptional regulation of TRIB1. This is in line with our
previous findings where we showed that overexpression of TRIB1
3’UTR protects the endogenous mRNA, probably via titrating
out factors (miRNAs or RNA binding proteins) that regulate the
stability of the mRNA (2). To characterize the extent by which
the effect of TRIB1 3’UTR may be mediated by interaction with
miRNAs, we carried out a comprehensive in silico analysis using
multiple miRNA-target prediction tools, including StarBase
which is supported by CLIP-seq experimental data (http://
starbase.sysu.edu.cn/) (Figure 3E). This analysis predicted that
the 3’UTR of TRIB1 can potentially interact with a total of 1,237
distinct miRNAs. Amongst these, 285 high confidence miRNAs
were identified in miRbase v.22 (ftp://mirbase.org/pub/mirbase/
CURRENT/). Annotation of high confidence miRNAs was based
on RNA deep sequencing data and pattern of mapped reads, as
described in details by Kozomara and colleagues (25); 35 high
confidence miRNAs were predicted to bind to the TRIB1 3’UTR
by at least 3 prediction tools (Supplementary Table 6). Next, we
selected miR-101-3p and miR-132-3p for experimental
validation: they were listed as high-confidence miRNAs and
were predicted by the majority of the tools that we used, also
showing evolutionarily conserved binding-sites in the 3’UTR of
TRIB1 mRNA (Figures 3B, C and Supplementary Figure 4).
Additionally, they have been previously implicated in the
literature to regulate inflammation and macrophage function
(Supplementary Table 7). To determine the impact of these
miRNAs on TRIB1 expression, we transiently transfected
miRNA mimics and a negative control into human MDMs




FIGURE 3 | TRIB1 3’ UTR encodes for evolutionarily conserved miRNA binding sites. (A) Schematic representation of TRIB1 mRNA, showing the length of the
untranslated regions and the protein coding sequence. (B) Schematic overview of TRIB1 3’UTR multi-species alignment, generated with the software DNASTAR
Lasergene (v16). (C) TRIB1 3’UTR alignment tree, generated with the software DNASTAR Lasergene (v16) using the ClustalW algorithm. (D) Relative luciferase
activity measured in HEK293T cell line after transfection of renilla luciferase reporter (control, 95 ng/well) and TRIB1 3’UTR renilla luciferase reporter (TRIB1 3’UTR,
95 ng/well) along with a firefly luciferase reporter plasmid (5 ng/well), used for data normalization (n = 12, biological replicates, unpaired t-test, ***p < 0.001).
(E) Overview of miRNAs-target prediction analysis: seven different tools (miRanda, TargetScan, StarBase, miRDB, miRwalk, TarBase, and MicroT-CDS) were used to
predict miRNAs targeting the 3’UTR of TRIB1; the list of distinct miRNAs was filtered selecting only “high-confidence” miRNAs (according to miRbase v.22) and
miRNAs predicted at least by three different tools.
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marrow–derived macrophages (iBMDMs). The endogenous
mRNA expression of TRIB1 was significantly reduced by miR-
101-3p (p = 0.001) and miR-132-3p (p = 0.02), compared to the
control (Figures 4A, B). Murine Trib1 mRNA was also
downregulated, but the changes were not statistically
significant (Figure 4C). Next, we investigated the endogenous
expression of these miRNAs in human unpolarized (Mun) and
polarized (M1 and M2a) macrophages by using RT-qPCR. We
found that miR-101-3p was upregulated in M1 but not in M2
macrophages, compared to unpolarized cells (p = 0.04) (Figure
4D). The expression of miR-132-3p did not change in either M1
or M2 macrophages (Figure 4E). To investigate the biological
relevance of candidate miRNAs, we performed a KEGG
enrichment pathway analysis on the subset of target genes for
each miRNA, focussing on those that are expressed in human
macrophages. To this aim, we used an RNA seq dataset
performed on human polarized macrophages, previously
generated in our group (DOI: 10.17632/j2hmt7k9fh.1).
Interestingly, we found shared enriched terms between miR-
101-3p and miR-132-3p target genes, including MAPK signaling
pathway (Figures 4F, G), which is well established to control
macrophage inflammatory responses (33) and is also regulated
by TRIB1 (34–36). Additionally, we found in our KEGG analysis
(Figure 4G) that several miR-132-3p target genes expressed in
macrophages, have been suggested to be involved in prostate
cancer, a disease in which TRIB1 has been implicated (10, 11, 37).
Additionally, it is well established that miR-132-3p acts as an
onco-suppressor miR in prostate cancer, as several publications
have reported (38, 39).
miR-101-3p Has a Functional Binding
Site in the 3’UTR of TRIB1
miR-101-3p, a miRNA known to regulate inflammatory
responses in monocyte/macrophages (40, 41), was predicted to
bind to the 3’UTR of TRIB1 between positions 1526-1532 (7mer-
m8 site) and 1424-1430 (7mer-A1 site) (Supplementary Table
7). However, we focussed on the 7mer-m8 site, as it was
predicted by all the tools used and was the most conserved
(Supplementary Table 7); this is an established factor of likely
biological relevance (19). Furthermore, the interaction is
characterized by one of the most effective canonical seed
region types, an exact match to position 2–8 of the mature
miRNA (Figure 5A), which strongly correlates with targeting
efficiency (19, 42). To substantiate the direct interaction between
miR-101-3p and TRIB1 3’UTR, we co-transfected the TRIB1
3’UTR reporter plasmid and 50nM of miR-101-3p mimic or
negative control in HEK293T cells and carried out a luciferase
reporter assay. Overexpressing miR-101-3p led to a significant
reduction of the TRIB1 3’UTR reporter activity compared to
control (~45% reduction, p = 0.006) (Figure 5B). In contrast,
miR-101-3p overexpression had no effect on reporter expression
with a TRIB1 3’UTR mutant lacking the 7 nucleotides
complementary to the miR-101-3p seed region (p = 0.8)
(Figures 5A, C), confirming that the predicted miR-101-3p
binding site between positions 1526-1532 is in fact targeted by
miR-101-3p. Conversely, a miRNA inhibitor, which is designed
to antagonize the activity of the endogenous miR-101-3p, led to a
significant increase of the luciferase activity (~16% increase, p =
0.005) and had no effect when co-transfected together with a
control plasmid, without the 3’UTR of TRIB1 (p = 0.4) (Figure
5D). Next, we evaluated the effect of miR-101-3p mimic on
endogenous TRIB1 protein levels in transfected human MDMs,
as we previously showed that the mRNA of both human and
murine TRIB1 was negatively downregulated (Figures 5D, E).
Upon transfection of the mimic, TRIB1 protein was reduced by
approximately 60%, compared to control (p = 0.03) (Figures
5E, F). Finally, we investigated whether the activity of miR-101-3p
on endogenous TRIB1 mRNA and protein levels in macrophages
is due to their direct physical interaction. To this aim, we
transiently transfected MDMs with a miR-101/TRIB1 TSB. This
is an antisense oligonucleotide designed to selectively compete
with miR-101-3p for binding the TRIB1 3’UTR. It binds to the
target with high affinity, preventing the endogenous miRNA from
binding to the same region and without activating the RISC
complex (Figure 5G). The TSB treatment caused a significant
increase of TRIB1 mRNA (~30%, p = 0.004) compared to control
(Figure 5H), suggesting that a direct interaction between miR-
101-3p and TRIB1 occurs in human macrophages. However, we
did not observe a significant increase in the Trib1 protein (p = 0.2).
This was likely due to an individual donor, as shown in the line
graph in Figure 5I and in the immunoblot (Figure 5J, donor 2).
Nevertheless, our data indicate that miR-101-3p is a negative,
direct regulator of TRIB1 in macrophages.
miR-101-3p Drives a Pro-Inflammatory
Phenotype in Human Macrophages
In macrophages, miR-101-3p was previously identified as a
direct regulator of the dual specificity phosphatase 1 (DUSP1)
(40) and ATP-binding cassette transporter A1 (ABCA1) (41)
genes. This was associated with the activation of p38 and JNK
and inhibition of cholesterol efflux under inflammatory and non-
inflammatory conditions, respectively (40, 41). We confirmed
the negative effect of miR-101-3p overexpression on DUSP1 and
ABCA1 mRNA in unpolarized human MDMs (Supplementary
Figures 6A, B) and its impact on cholesterol efflux to HDL
(Supplementary Figure 6C). We next analyzed the expression of
pro- and anti-inflammatory macrophage markers by RT-qPCR.
We observed that miR-101-3p significantly increased the mRNA
levels of IL-6, IL-8, TNF-a, CD80, and CD86 (Figure 6A), but
had no effect on the anti-inflammatory markers CD36, CD163
and IL-4 (Figure 6B). We performed IL-8 ELISA on MDMs
transfected with miR-101-3p mimic and miR-101/TRIB1 TSB
and found that the mimic enhanced IL-8 secretion (p = 0.007),
while the TSB diminished it (p = 0.01) (Figure 6C). Additionally,
we tested the impact of miR-132-3p, which downregulated the
mRNA of TRIB1 in both human and murine macrophages (see
Figure 4B). IL-8 secretion was significantly increased in response
to miR-132-3p mimic (p = 0.01), suggesting that TRIB1 is a
regulator of IL-8, downstream of the miRNAs tested. Overall, we
conclude that miR-101-3p and miR-132-3p drive an
inflammatory phenotype in human macrophages, at least in
part by targeting TRIB1.
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FIGURE 4 | TRIB1 is post-transcriptionally regulated by miRNAs. (A, B) Relative mRNA expression of TRIB1 normalized to the housekeeping GAPDH in MDMs
transiently transfected with miR-101-3p and miR-132-3p mimics (n = 5–8, biological replicates, paired t-test, **p < 0.01, *p < 0.05). (C) Relative mRNA expression of
murine Trib1 normalized to the housekeeping Gapdh in iBMDMs transiently transfected with miR-101-3p and miR-132-3p mimics (n = 4, biological replicates,
unpaired t-test, no statistical significance p > 0.05). (D, E) Relative expression of miR-101-3p and miR-132-3p normalized to the housekeeping U6 in unpolarized
and M1- and M2- polarized MDMs (n = 3, biological replicates, repeated measure one way ANOVA with Dunnett’s post-test, *p < 0.05, no statistical significance
p > 0.05). (F, G) KEGG enrichment pathway analysis of miR-101-3p and miR-132-3p target genes, predicted by using TargetScan and selecting macrophage-
specific genes (from RNA-seq deposited at DOI: 10.17632/j2hmt7k9fh.1). Data are presented as mean ± SEM (scatter dot plot, where each dot represents an
individual donor of MDMs or different passage of iBMDMs). Transient transfection of both DNAs and RNAs was carried out for 24 h. Mimics/control were used at
50 nM. RT-qPCR data were analyzed using the 2(−DCt) method. KEGG analysis was performed with the GOseq R package.
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FIGURE 5 | miR-101-3p has a functional binding site in the 3’UTR of TRIB1. (A) Schematic alignment of miR-101-3p with the 3’UTR of TRIB1 and its “binding site”
mutant. (B) Relative luciferase activity measured in HEK293T cell line after co-transfection of the TRIB1 3’UTR renilla reporter (95 ng/well) with miR-101-3p mimic
and a negative control (+firefly luciferase reporter, 5 ng/well), (n = 9, biological replicates, unpaired t-test, **p < 0.01). (C) Relative luciferase activity measured in
HEK293T cell line after co-transfection of the TRIB1 3’UTR renilla reporter “mutant” (95 ng/well) with miR-101-3p mimic and a negative control (+ firefly luciferase
reporter, 5 ng/well), (n = 7, biological replicates, unpaired t-test, no statistical significance p > 0.05). (D) Relative luciferase activity measured in HEK293T cell line
after co-transfection of the renilla luciferase reporter (control, 95 ng/well) and TRIB1 3’UTR renilla reporter (TRIB1 3’UTR, 95 ng/well) with miR-101-3p inhibitor and a
negative control (+ firefly luciferase reporter, 5 ng/well), (n = 6, biological replicates, ordinary one-way ANOVA with Sidak’s post-test, **p < 0.01, no statistical
significance p > 0.05). (E, F) Trib1 protein levels relative to the housekeeping a-tubulin in MDMs transiently transfected with miR-101-3p mimic/negative control and
representative immunoblot (n = 5, biological replicates, paired t-test, *p < 0.05). (G) Schematic representation of TSB/endogenous miRNA competition for the target
site. (H) Relative TRIB1 mRNA expression normalized to the housekeeping GAPDH in MDMs transiently transfected with miR-101/TRIB1 TSB and a negative control
(n = 7, biological replicates, paired t-test, **p < 0.01). (I, J) Trib1 protein levels relative to the housekeeping Hsp90 in MDMs transiently transfected with miR-101/
TRIB1 TSB/negative control and representative immunoblot (n = 4, biological replicates, paired t-test, no statistical significance p > 0.05). Data are presented as
mean ± SEM (scatter dot plot where each dot represents an individual donor of MDMs or different passages of HEK293T cells). Each biological replicate represents
the average of 3 technical replicates. Transient transfection of both DNAs and RNAs was carried out for 24 h. Mimic/control, inhibitor/control and TSB/control were
used at 50, 25, and 50 nM, respectively. RT-qPCR data were analyzed using the 2(−Dct) method.
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TRIB1 Is a Target of miRNAs
Downregulated in Prostate Cancer
It is widely reported that in prostate cancer the majority of
dysregulated miRNAs are either silenced by epigenetic
modifications or downregulated (43–45). At the same time,
TRIB1 has been reported to be upregulated in this cancer (10).
To address the hypothesis that TRIB1 upregulation occurs as a
result of downregulation of endogenous miRNAs, we first
assessed the endogenous TRIB1 expression in in vitro models
of prostate cancer. To this end we used PWR1E and RWPE1 as
normal prostate epithelial cells and PC3 and LNCAP as cancer
cell lines. The mRNA expression of TRIB1 was significantly
upregulated in PC3 and LNCAP cells, compared to RWPE1,
non-cancer prostate epithelial cells (Figure 7A). Next, we used
the miRCancer database to download the list of miRNAs
reported to be dysregulated in prostate cancer and found that
21 downregulated miRNAs are also predicted to target the
3’UTR of TRIB1, according to TargetScan (Figure 7B and
Supplementary Table 7). Among them, we selected miR-132-
3p and miR-224-5p, since both of these miRNAs are established
to be silenced in prostate cancer (38, 46). Additionally, as
described above, miR-132-3p is a potential regulator of TRIB1
in both human and murine macrophages and miR-224-5p has
also been already implicated in the regulation of this
pseudokinase in prostate cancer (47). Therefore, we assessed
the expression of these miRNAs in PC3 and LNCAP cells.
Considering our previous findings, we included miR-101-3p as
it was also listed as miRNA downregulated in prostate cancer,
according to the miRCancer database. miR-132-3p was




FIGURE 6 | miR-101-3p drives a pro-inflammatory phenotype in human macrophages. (A, B) Relative mRNA expression of pro-inflammatory IL-6, IL-8, TNF-a c,
CD80, and CD86 and anti-inflammatory macrophage markers CD36, CD163 and IL-4 normalized to the housekeeping GAPDH in MDMs transiently transfected with
miR-101-3p mimic and a negative control. (C) Levels of IL-8 protein (pg/ml) measured from the supernatants of MDMs transiently transfected with miRNAs mimics
and miR-101-3p/TRIB1 TSB. Data are presented as mean ± SEM (scatter dot plot where each dot represents an individual donor of MDMs). Each biological
replicate represents the average of 3 technical replicates; (n = 4–8, biological replicates, paired t-test, **p < 0.01, *p < 0.05, no statistical significance p > 0.05).
Transfection was carried out for 24 h, employing 50 nM of test and control RNAs. RT-qPCR data were analyzed using the 2(−Dct) method.
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FIGURE 7 | TRIB1 is a target of miRNAs downregulated in prostate cancer. (A) Relative mRNA expression of TRIB1 normalized to the housekeeping GAPDH in
prostate cancer cell lines (n = 4–6, biological replicates, ordinary one-way ANOVA with Sidak’s post-test, ****p < 0.0001, ***p < 0.001, **p < 0.01, no statistical
significance p > 0.05). (B) Flowchart for the detection of miRNAs downregulated/silenced in prostate cancer and potentially targeting the 3’UTR of TRIB1. (C–E)
Relative expression of miR-132-3p, miR-224-5p and miR-101-3p normalized to the housekeeping U6 in a panel of prostate cancer and control cell lines (n = 4–6,
biological replicates, ordinary one-way ANOVA with Sidak’s post-test, ****p < 0.0001, **p < 0.01, ND not detected, ns p > 0.05). (F) Schematic representation of
miR-132-3p binding sites in two different positions of TRIB1 3’UTR. (G, H) Relative luciferase activity measured in HEK293T cell line after co-transfection of co-
transfection of the TRIB1 3’UTR renilla reporter (95 ng/well) and miR-132-3p mimic/control (left) and miR-132-3p inhibitor/control (right) (+ firefly luciferase reporter,
5 ng/well) (n = 3–5, biological replicates, unpaired t-test, *p < 0.05, no statistical significance p > 0.05). Data are presented as mean ± SEM (scatter dot plot where
each dot represents different passages of cell lines). Each biological replicate represents the average of 3 technical replicates. Transfection of plasmids and RNAs
was carried out for 24 h. Mimic/control and inhibitor/control were used at 50 and 25 nM, respectively. RT-qPCR data were analyzed using the 2(−Dct) method.
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controls (Figure 7C), while miR-224-5p was not detectable in the
cancer cells (Figure 7D). On the contrary, the endogenous
expression of miR-101-3p in PC3 and LNCAP lines was not
significantly different from the controls (Figure 7E). Therefore,
we next focused on the activity of miR-132-3p. miR-132-3p has two
predicted binding sites on the 3’UTR of TRIB1 (Figure 7F). Despite
not being highly conserved, the target sites are both characterized
by a 7mer-m8 seed region (Supplementary Table 7). When tested
in a luciferase assay, miR-132-3p mimic led to a significant
reduction of the TRIB1 3’ UTR reporter activity, compared to
control (p = 0.02) (Figure 7G). Transfection of the inhibitor led to
an increase in the luciferase activity, on average, however this did
not reach statistical significance (p = 0.09) (Figure 7H). We note
that miRNA inhibitors are often less effective in rescuing miRNA-
target expression, especially when the endogenous miRNAs they
target are present at low levels. Next, we performed a transient
transfection of PC3 cells with TRIB1 siRNA/scramble and miR-
132-3p mimic/control and analyzed the gene expression profile
of pro-inflammatory cytokines and cancer-related genes and
found similar signatures. The assessment of TRIB1 mRNA
downregulation induced by the siRNA and miR-132-3p is
shown in Figures 8A, D, respectively. Either condition led to
significant upregulation of pro-inflammatory cytokines (IL-6, IL-
8 and IL-1b) (Figures 8B, E), in line with our above presented
data obtained in human macrophages. The immune checkpoint
regulator gene, PD-L1, was also significantly increased in both
conditions, while the extracellular matrix glycoprotein SPAR-C
was enhanced only in PC3 cells treated with TRIB1 siRNA (p =
0.01) (Figures 8C, F), hinting a role for TRIB1 in the regulation
of cancer immune escape and invasion properties. Put together,
these results suggest that the miR-132-3p/TRIB1 axis may be a
regulator of the immunological profile of prostate cancer.
DISCUSSION
Since their discovery 20 years ago (48, 49), Tribbles proteins have
gained significant attention and have been implicated in many
different pathologies, including cancer, cardiovascular disease,
and metabolic disorders (5, 9, 10, 50–52). The role of TRIB1 has
been particularly studied in myeloid cells and adipose tissue, and
linked to the regulation of anti-inflammatory macrophage
polarization and inflammatory responses (7, 8, 32). Recently, it
has emerged that TRIB1 is often overexpressed in prostate cancer
and is associated with cancer risk, but not with aggressiveness
and survival (37). Although TRIB1-mediated signaling pathways
are well characterized (1, 2, 34, 53), the upstream mechanisms
underlying its regulation remain unknown. The observation that
altered expression of Trib1 in myeloid cells leads to significant
changes in the phenotypes of liver and adipose macrophages
provides further evidence for the importance of this




FIGURE 8 | TRIB1 knock-down and miR-132-3p overexpression in PC3 cell lines. (A, D) Relative TRIB1 mRNA expression normalized to the housekeeping GAPDH
in PC3 cell line transiently transfected with siTRIB1/Scramble and miR-132-3p/control (n = 3–4, biological replicates, unpaired t-test, ****p < 0.0001, *p < 0.05).
(B, C, E, F) Relative mRNA expression of inflammatory markers and cancer-related genes normalized to the housekeeping GAPDH in in PC3 cell line transiently
transfected with siTRIB1/Scramble and miR-132-3p/control (n = 4, biological replicates, unpaired t-test, **p < 0.01, *p < 0.05, no statistical significance p > 0.05).
Data are presented as mean ± SEM (scatter dot plot where each dot represents a different passage of PC3 cells). Each biological replicate represents the average of
three technical replicates. Transfection was carried out for 24 h. Mimic/control and siTRIB1/Scramble were used at 50 nM. RT-qPCR data were analyzed using the 2
(−Dct) method.
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This prompted us to explore upstream factors, with focus on
miRNAs, that may be important in regulating Trib1 expression
levels in macrophages, as well as exploring whether similar
regulatory mechanisms may control TRIB1 levels in cellular
models of PCa. Thus, we looked at the post-transcriptional
regulation of TRIB1, with a focus on the importance of its 3’
UTR. This region of eukaryotic mRNAs has been extensively
studied and several types of regulatory elements contributing to
the control of mRNA (in)stability have been described ([a recent
review, see (54)]. A study conducted in murine embryonic stem
cells reported that TRIB1 mRNA has a half-life shorter than 1 h
and it was ranked among the top 50 most unstable genes (12). As
the human TRIB1 mRNA is characterized by a 2 kb long and
conserved 3’UTR, we proposed that regulatory sequences within
this may contribute to the control of TRIB1 mRNA stability,
including a role for miRNAs. In line with this hypothesis, we
showed that the 3’UTR of TRIB1 had a strong, negative effect on
luciferase expression by using a reporter assay. Our in-silico
analysis indicated that multiple “high-confidence” miRNAs are
predicted to bind to the 3’UTR of TRIB1. So far, only miR-23a
and miR-224-5p have been experimentally validated and shown
to downregulate TRIB1 expression in hepatocellular carcinoma
and prostate cancer models, respectively (47, 55). Specifically, we
demonstrated that miR-101-3p and miR-132-3p were able to
negatively modulate both human and murine TRIB1 mRNA
expression in macrophages. To elucidate the biological impact of
these miRNAs, we performed an enrichment pathway analysis
using their predicted target genes, selecting only those expressed
by human macrophages. Among the top 10 enriched terms for
miR-101-3p target genes we observed MAPK and chemokine
signaling pathways, both of which have previously been shown to
be extensively regulated via Trib1. We demonstrated that the
experimental overexpression of miR-101-3p in primary human
macrophages led to a significant increase in the mRNA levels of
pro-inflammatory markers, such as IL-6, IL-8, TNF-a, CD80, and
CD86. It has been previously reported that TRIB1 regulates the
activity of the IL-8 promoter in a gene reporter assay (2). More
recently, it was shown that TRIB1 negatively regulates IL-8
secretion by inhibiting IKB-zeta in prostate cancer cells (11).
To investigate the consequences of the putative interaction
between endogenous miR-101-3p and TRIB1 mRNA, we
evaluated the impact of miR-101-3p on both TRIB1 expression
and IL-8 secretion by employing a TSB, a molecule designed to
selectively prevent the endogenous miR from binding the mRNA
of only TRIB1, without altering the miRNA expression itself. The
TSB caused a significant increase in the steady-state mRNA of
TRIB1 and a reduction in IL-8 secretion. Similarly, we showed
that miR-132-3p mimics downregulated TRIB1 and enhanced
secreted IL-8 protein levels. Therefore, our findings indicate that
endogenous miRNAs are able to control TRIB1 expression and,
in turn, regulate IL-8 via targeting TRIB1. Of note, miR-132-3p
was also shown to increase IL-8 levels in human adipocytes by
targeting SirT1 and thus activating NF-kB (56), a key activator of
inflammation and the latter also being a known TRIB1 target (7,
57). In light of our data, it is plausible that the miR-132-3p/
TRIB1 regulatory axis may play a part in this. However, we also
explored the interaction between miR-132-3p and TRIB1 in the
context of prostate cancer. Our KEGG analysis of miR-132-3p
predicted targets showed an enrichment of genes involved in
prostate cancer. Although miR132 did not show the highest
number of gene reads in PCa, we focused on this pathway
because miR-132-3p is usually silenced by promoter
hypermethylation in prostate cancer (38). A number of studies
reported that restoring miR-132-3p expression in prostate cancer
resulted in the suppression of cell proliferation, migration and
invasion (38, 39, 58, 59). In addition to miR-132-3p, we
identified 20 other miRNAs which are either silenced or
downregulated in prostate cancer and also predicted to target
TRIB1, with multiple binding sites, including miR-101-3p. Thus,
we speculate that the downregulation of endogenous miRNAs
could, at least in part, account for the elevated expression of
TRIB1 in prostate cancer, the causes of which have not been
established yet (10, 37, 47). Here, we assessed the endogenous
expression of miR-132-3p, miR-224-5p and miR-101-3p in a
panel of prostate cancer cell lines and controls. We selected miR-
132-3p and miR-101-3p as we validated their impact on
TRIB1 in human macrophages, and miR-224-5p as a positive
control. In fact, miR-224-5p has previously been shown to be
downregulated in prostate cancer and to target TRIB1 and inhibit
prostate cancer growth in vitro (47). We found that miR-132-3p
and miR-224-5p were significantly downregulated in cancer cells
compared to controls, while the expression of miR-101-3p did
not show any significant changes among the different cell lines.
As the interaction between TRIB1 and miR-224-5p has been
functionally validated already (47), we focussed on miR-132-3p,
showing that the downregulation of TRIB1 by either a small
interfering RNA or miR-132-3p mimic led to similar
transcriptomic signatures in PC3 cells and confirmed
the impact of the pseudokinase on IL-6 and IL-8 mRNA
expression, even in non-myeloid cells. Of interest, MSR1
expression has also been enhanced in the presence of
overexpressed TRIB1. In addition to being a widely used
marker of M2-like macrophages, this gene has also been linked
to the development of prostate cancer (60, 61). The immune
checkpoint regulator gene, PD-L1 also increased in both
conditions, suggesting a role for TRIB1 in regulating the
“immune escape” of prostate cancer. While our data presented
in this paper provides evidence for TRIB1 altering macrophage
phenotypes (pro- vs. anti-inflammatory) both in murine
metabolic tissues and human monocyte-derived macrophages,
further mechanistic studies are required to elucidate the full
impact of these TRIB1-mediated changes on prostate cancer
cells. However, our data supports the hypothesis that the role of
TRIB1 in prostate cancer is, at least in part, linked to macrophage
polarization and function, as a recent work has suggested (11). In
fact, Liu and colleagues demonstrated that high levels of TRIB1
in prostate cancer correlate with CD163+ macrophage
infiltration. In addition, they showed that TRIB1 inhibits the
secretion of cytokines from prostate cancer cells via inhibition of
IKB-zeta. This, in turn, leads to the differentiation of anti-
inflammatory M2-like macrophages in the surrounding
microenvironment, which supports tumour growth (11). Of
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particular interest, a recent from Carracedo and his colleagues
(62) demonstrates a cancer cell-intrinsic role for TRIB1 in
prostate cancer by showing that TRIB1 often overexpressed in
PCa, and that overexpression of this gene in the prostate
epithelium accelerates tumourigenesis in a mouse model. Thus,
our data and the literature collectively suggest an important
regulatory role for TRIB1 both in macrophages and tumour cells,
thus may provide a novel mechanism for the interplay between
the tumour microenvironment and cancer cells.
In summary, in this report, we have demonstrated that TRIB1
is subject to post-transcriptional regulation by miRNAs. By using
a systematic miRNA-target prediction analysis, we identified a
number of “high-confidence” miRNAs predicted to bind to the
3’UTR of TRIB1 through a canonical seed region matching. We
experimentally validated the interaction of the 3’UTR of TRIB1
with miR-101-3p and miR-132-3p in human macrophages and
prostate cancer, respectively, showing that they control TRIB1
expression and, in turn, alter the mRNA and protein levels of IL-
8. Of note, data we present on miRNA-132-3p action is lacking
TSB blockade validation, similar to as shown for miRNA-101-3p,
due to constrains of overall available primary macrophage cell
numbers used in these experiments. However, we also recognize
that the presented association between TRIB1-regulating
miRNAs and the development of PCa is largely correlative in
nature, thus future investigations will be required to further
substantiate the biological relevance of these findings.
We also note that some of the data presented here is preliminary
in nature and analysis of larger number of replicates have been
severely hampered by the impact of COVID19 pandemic imposed
restrictions. In addition to technical challenges of restricted working
patterns, this disease is driving a severe monocyte/macrophage
response is often asymptomatic or very mildly symptomatic in
younger adults, thus controlling for potential effects of SARS-COV-
2 in human monocyte-derived macrophages obtained from healthy
volunteers that may interfere with our readouts is very challenging.
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SUPPLEMENTARY FIGURE 1 | Immunofluorescence: isotype controls and
ATM staining. FFPE adipose tissue from myeloid Trib1 mice were stained with F4/
80 (red) and the anti-inflammatory/M2 marker YM1 (green). Representative image of
isotype controls and ATM staining is shown. Enlarged image of the boxed area is
shown illustrating F4/80+ macrophage and dual positive (F4/80+ YM1+)
macrophage.
SUPPLEMENTARY FIGURE 2 | Genetic manipulation of myeloid Trib1 alters
ATM phenotype in vivo. (A) Representative image of YM1 immunostaining of
adipose tissue sections from Trib1mWT, Trib1mKO and Trib1mTgmice. Scale: 100µm.
Enlarged image of marked area is also shown. Each n represents the mean of at
least 3 fields of view from an individual mouse. (B) Quantification of F4/80 positive
cells in adipose tissue sections from Trib1mWT, Trib1mKO and Trib1mTg mice. (n = 4–
9 biological replicates, ordinary one-way ANOVA with Sidak’s post-test, no
statistical significance p > 0.05). (C) Quantification of YM1 positive cells relative to
F4/80 in adipose tissue sections from Trib1mWT, Trib1mKO and Trib1mTgmice (n = 3–
6, biological replicates, ordinary one-way ANOVA with Sidak’s post-test, *p < 0.05,
no statistical significance p > 0.05). Each n represents an individual mouse; mice
were obtained from two independent breeding cohorts and were stained per
cohort, each including WT litter-mate controls. At least 3 independent fields of view
were examined per mouse.
SUPPLEMENTARY FIGURE 3 | Confirmation of TRIB1 overexpression in
human macrophages. Relative TRIB1 mRNA expression normalized to the
housekeeping GAPDH in MDMs transiently transfected with TRIB1 overexpression
plasmid and a control plasmid (n = 4, biological replicates, paired t-test, no
statistical significance p > 0.05). Data are presented as mean ± SEM (scatter dot
plot where each dot represents an individual donor of MDMs). Biological replicate
represents the average of 3 technical replicates. Transfection was carried out for
24 h, employing 2 µg of plasmid per well (6 well plate). RT-qPCR data were analyzed
using the 2(−Dct) method.
SUPPLEMENTARY FIGURE 4 | TRIB1 3’UTR mega alignment. Overview of
TRIB1 3’UTR sequences alignment in different species, generated with the software
DNASTAR Lasergene (v16); miR-101-3p and miR-132-3p binding sites are
highlighted in red and black, respectively.
SUPPLEMENTARY FIGURE 5 | Confirmation of miRNAs overexpression in
human macrophages. Relative expression of miR-101-3p and miR-132-3p
normalized to the housekeeping U6 in MDMs transiently transfected with miRNA
mimics (n = 5–8, biological replicates, paired t-test, ***p < 0.001). Data are
presented as mean ± SEM (scatter dot plot where each dot represents an individual
donor of MDMs). Biological replicates represent the average of 3 technical
replicates. Transfection was carried out for 24 h, employing 50nM of mimics and
negative control. RT-qPCR data were analyzed using the 2(−Dct) method.
SUPPLEMENTARY FIGURE 6 | Effect of miR-101-3p on previously validated
targets: DUSP1 and ABCA1. (A, B) Relative mRNA expression of DUSP1 and
ABCA1 normalized to the housekeeping GAPDH in MDMs transiently transfected
with miR-101-3p mimic and a negative control (n = 4–7, biological replicates, paired
t-test, **p < 0.01, *p < 0.05). (C) Percentage of total cholesterol efflux to HDL
measured in MDMs transiently transfected with miR-101-3p mimic and inhibitor (n =
6, biological replicates, paired t-test, **p < 0.01). Data are presented as individual
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points (A, B) and as mean ± SEM (scatter dot plot) (C). Each dot represents an
individual donor of MDMs; biological replicates represent the average of 3 technical
replicates. Transfection was carried out for 24 h, employing 50 nM of mimic/control
and 25 nM of inhibitor/control. RT-qPCR data were analyzed using the 2(−Dct)
method. As miRNA mimic and inhibitor were used at different concentrations and
along with their controls (negative control mimic and negative control inhibitor) we
used the paired t-test.
SUPPLEMENTARY TABLE 1 | List of RNA constructs used for transient
transfection.
SUPPLEMENTARY TABLE 2 | List of primary and secondary antibodies used
for western blot (WB) and immunofluorescence (IF) experiments.
SUPPLEMENTARY TABLE 3 | List of RT-qPCR primers.
SUPPLEMENTARY TABLE 4 | List of PCR primers used for site-directed
mutagenesis.
SUPPLEMENTARY TABLE 5 | List of “high-confidence” miRNAs predicted to
target the 3’UTR of TRIB1 by 3 different prediction tools, along with their features
taken from TargetScan. The list of “high-confidence”miRNAs can be accessed and
downloaded using this link ftp://mirbase.org/pub/mirbase/CURRENT (miRbase
v.22).
SUPPLEMENTARY TABLE 6 | The table lists candidate miRNAs selected for
experimental validation and their features, according to TargetScan; both were
listed as “high-confidence”miRNAs, according to deep sequencing published data
(miRbase v.22).
SUPPLEMENTARY TABLE 7 | List of miRNAs downregulated/silenced in
prostate cancer and predicted to target the 3’UTR of TRIB1. miRNA-target
prediction analysis was performed by using TargetScan, miRanda and
Starbase. The list of dysregulated miRNAs in prostate cancer was taken from
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